Showing 9,981 - 10,000 results of 18,516 for search 'significantly ((((linear decrease) OR (((a decrease) OR (mean decrease))))) OR (larger decrease))', query time: 0.34s Refine Results
  1. 9981

    Raw data. by Kaitao Zhao (3617825)

    Published 2025
    “…Results revealed the MRE11–RAD50–NBS1 (MRN) complex as a potential factor. Transiently or stably knockdown of MRE11, RAD50 or NBS1 in hepatocytes before HBV infection significantly decreased viral markers, including cccDNA, while reconstitution reversed the effect. …”
  2. 9982

    Clinical and epidemiological data of patients. by Mailma Costa de Almeida (22057684)

    Published 2025
    “…CTG showed a significant reduction in pain within 24 hours in the per-protocol analysis (Log-rank <i><i>p</i></i> = <i><i>0.04</i></i>). …”
  3. 9983

    Supplementary Material for: SPECKLE TRACKING ECHOCARDIOGRAPHY IN TWIN PREGNANCIES AND THE ROLE OF GLOBAL LONGITUDINAL STRAIN AND PEAK SYSTOLIC STRAIN: A SYSTEMATIC REVIEW AND META-... by Meireson E. (20224101)

    Published 2024
    “…The global longitudinal strain in the right and left ventricle and the peak systolic strain in the right ventricle of the recipient MCDA twin is significantly decreased compared to the donor MCDA twin. 2D STE assessment was shown feasible and reproducible in MCDA pregnancies. …”
  4. 9984

    Image1_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  5. 9985

    Image2_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  6. 9986

    Image8_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  7. 9987

    Image5_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  8. 9988

    Image6_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  9. 9989

    Image3_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  10. 9990

    Image4_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  11. 9991

    Image7_Kidney outcomes associated with SGLT2 inhibitors compared to other glucose-lowering drugs: a real-world study from China.TIF by Xiang Xiao (44417)

    Published 2024
    “…Throughout the follow-up period, we observed a significant decrease in the rate of eGFR decline in patients using SGLT2i (4.94 mL/min/1.73 m<sup>2</sup> per year reduction compared to oGLDs, 95% CI: 4.73–5.15). …”
  12. 9992

    WHODAS Outcomes (ITT Analysis). by Mailma Costa de Almeida (22057684)

    Published 2025
    “…CTG showed a significant reduction in pain within 24 hours in the per-protocol analysis (Log-rank <i><i>p</i></i> = <i><i>0.04</i></i>). …”
  13. 9993

    Efficacy primary and secondary outcomes. by Mailma Costa de Almeida (22057684)

    Published 2025
    “…CTG showed a significant reduction in pain within 24 hours in the per-protocol analysis (Log-rank <i><i>p</i></i> = <i><i>0.04</i></i>). …”
  14. 9994

    Table 1_Influence of age and sex on the diagnostic accuracy of pleural fluid carcinoembryonic antigen for malignant pleural effusion: a post hoc analysis.docx by Dan-Ni Yang (17642947)

    Published 2025
    “…</p>Methods<p>We enrolled participants from a prospective cohort (SIMPLE) and a retrospective cohort (BUFF). …”
  15. 9995

    Supplementary Material for: Impact of Liraglutide 3.0 mg on Metabolic Dysfunction-Associated Steatotic Liver Disease in Individuals with Obesity: A Real-World Study by figshare admin karger (2628495)

    Published 2025
    “…Hepatic steatosis index (HSI) and non-alcoholic fatty liver disease (NAFLD) liver fat score also decreased significantly (HSI: 44.7 ± 6.2 to 42.2 ± 5.8 p<0.001; NAFLD liver fat score: 2.12 ± 2.90 to 0.43 ± 1.91, p<0.001). …”
  16. 9996
  17. 9997

    Image 1_The impact of tumor burden score on prognosis in patients after radical resection of hepatocellular carcinoma: a single-center retrospective study.tif by Junzhang Huang (13237880)

    Published 2024
    “…Purpose<p>This study examines the relationship between tumor burden score (TBS) and survival and recurrence following radical resection of hepatocellular carcinoma through a cohort study conducted in the Guangxi population of China.…”
  18. 9998

    Data Sheet 1_Promoting the development and approval of new traditional Chinese medicines in China: a pooled analysis of data from 2013 to 2024.docx by Xiaohong Long (20871797)

    Published 2025
    “…Post-reform, there has been a gradual increase in the number of new TCMs, with a notably significant rise in ancient classic formulas. …”
  19. 9999

    Table 1_The impact of tumor burden score on prognosis in patients after radical resection of hepatocellular carcinoma: a single-center retrospective study.docx by Junzhang Huang (13237880)

    Published 2024
    “…Purpose<p>This study examines the relationship between tumor burden score (TBS) and survival and recurrence following radical resection of hepatocellular carcinoma through a cohort study conducted in the Guangxi population of China.…”
  20. 10000